Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2026 Financial Results - GlobeNewswire
GlobeNewswire · Nov 5, 9:01 PM
Corvus Pharmaceuticals Announces Initial Data from Soquelitinib Clinical Trial in Patients with Autoimmune Lymphoproliferative Syndrome (ALPS) will be Presented at the 68ᵗʰ American Society for Hematology Annual Meeting & Exposition - Yahoo Finance
Yahoo Finance · Nov 4, 2:01 PM
Corvus Pharmaceuticals Announces Initial Data from - GlobeNewswire
GlobeNewswire · Nov 4, 2:01 PM
Market reactionShares rose 11% on Nov 6.
Corvus Pharmaceuticals is developing soquelitinib, an oral ITK inhibitor tested in atopic dermatitis and T-cell lymphoma; it is not approved.
Soquelitinib is an oral ITK inhibitor that rebalances T-cell activity. In a randomized Phase 1 cohort of 24 atopic dermatitis patients, 75% on drug reached EASI-75 versus 20% on placebo, and responses held through drug-free follow-up. SIERRA1, a 200-patient placebo-controlled Phase 2, is enrolling, with no readout date given. A registrational Phase 3 in relapsed PTCL is also enrolling. Cash of $215.2 million funds operations into the second quarter of 2028.
Thesis checklist
0 risks need attention
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Next decision point
Tests: SIERRA1 confirms efficacy in atopic dermatitis
Does soquelitinib improve EASI scores versus placebo at Week 12 in about 200 atopic dermatitis patients?
Strong, inconclusive and weak outcomes
What to look for in the result and how each would move the checklist
Price and material events
Select an event marker to read the update below. Marker colors show Thesis status.
Soquelitinib's Phase 2 SIERRA1 trial must confirm small Phase 1 atopic dermatitis results
Soquelitinib's Phase 2 SIERRA1 readout will determine whether ITK inhibition can disrupt the entrenched JAK inhibitor and biologic standard of care in moderate-to-severe atopic dermatitis
Soquelitinib Phase 1 cohort 4 AD data: 75% EASI 75 response
Soquelitinib AD Phase 1 interim data shows favorable safety & efficacy
About this history: every entry shows when the Thesis moved and what it said. The reasoning behind each move (the evidence, the analysis and the source filing) and the earnings write-ups are part of a subscription.
Dates, trials and completed outcomes are open to everyone. What each upcoming milestone hinges on is part of a subscription.
Disease areas: Blood cancers, Other cancers, Lung and respiratory diseases, Skin diseases
Catalyst calendar · Upcoming FDA decisions · Thesis changes
Competitive landscape
7 peers tracked
Cash: Market-data provider estimate; measurement period unavailable.
Debt: Market-data provider estimate; a complete comparable filing balance is unavailable.
Quarterly burn: Estimated from trailing free cash flow; measurement period unavailable.
Net cash and estimated runway require verified matching measurement periods. Missing debt components are not assumed to be zero.
Runway: No underlying guidance available.